Department of Cardiology, Guangdong General Hospital and Guangdong Cardiovascular Institute, Guangzhou, China.
J Hypertens. 2009 Nov;27(11):2278-82. doi: 10.1097/HJH.0b013e328330b654.
Most of the known actions of angiotensin II are mediated by the angiotensin II type 1 receptor (AGT1R). The adenine/cytosine(1166) (A/C(1166)) polymorphism of the AGT1R gene has been shown to be associated with hypertension and hypertension-related diseases. Thus, it may have the potential to predict the blood pressure response of patients with hypertension to angiotensin-converting enzyme inhibitors (ACEIs).
To investigate the association between the A/C(1166) polymorphism and the blood pressure response to ACEIs in a hypertensive cohort.
After a 2-week, single-blind, placebo run-in period, ACEIs were administered for 6 weeks to 509 hypertensive patients. The polymorphism was determined by PCR followed by restriction enzyme digestion.
The AA genotype, AC genotype, and CC genotype were present in 464 (91.2%), 44 (8.6%), and 1 (0.2%) of patients, respectively. As the frequency of the C allele was quite low (0.05), the genotypes were classified according to the presence or absence of the C allele. After 6 weeks of treatment, the systolic blood pressure reductions in patients with the AA genotype and AC + CC genotype were 14.3 +/- 12.6 and 14.1 +/- 12.2 mmHg, respectively (P = 0.908). The diastolic blood pressure reductions in patients with the AA genotype and AC + CC genotype were 8.6 +/- 7.1 and 8.8 +/- 6.9 mmHg, respectively (P = 0.816). There were no differences in the changes in systolic or diastolic blood pressure after treatment among the two genotype groups.
The AGT1R A/C(1166) polymorphism does not predict the response to antihypertensive treatment with ACEIs in Chinese hypertensive patients.
血管紧张素 II 的大多数已知作用是通过血管紧张素 II 型 1 受体（AGT1R）介导的。AGT1R 基因的腺嘌呤/胞嘧啶（1166）（A/C（1166））多态性已被证明与高血压和与高血压相关的疾病有关。因此，它可能有潜力预测高血压患者对血管紧张素转换酶抑制剂（ACEIs）的血压反应。
研究血管紧张素 II 型 1 受体基因 A/C（1166）多态性与 ACEIs 治疗高血压患者血压反应之间的关系。
在为期 2 周的单盲、安慰剂导入期后，509 名高血压患者接受 ACEIs 治疗 6 周。通过聚合酶链反应（PCR）和随后的限制性内切酶消化确定多态性。
AA 基因型、AC 基因型和 CC 基因型分别在 464（91.2%）、44（8.6%）和 1（0.2%）名患者中存在。由于 C 等位基因的频率相当低（0.05），因此根据 C 等位基因的存在与否对基因型进行分类。治疗 6 周后，AA 基因型和 AC+CC 基因型患者的收缩压降低分别为 14.3+/-12.6mmHg 和 14.1+/-12.2mmHg（P=0.908）。AA 基因型和 AC+CC 基因型患者的舒张压降低分别为 8.6+/-7.1mmHg 和 8.8+/-6.9mmHg（P=0.816）。治疗后两组患者的收缩压或舒张压变化无差异。
AGT1R A/C（1166）多态性不能预测中国高血压患者 ACEIs 降压治疗的反应。
